GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

The FTSE 100 tumbled 2.92 percent on Wednesday, shedding 231.05 points to close at 7,679.48 points as U.S. President ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

Robert F. Kennedy Jr. is set to significantly cut the size of HHS, reshaping the nation’s health agencies and closing ...

Blujepa interferes with that process, which prevents the bacteria from replicating and producing more bacteria that can ...

British pharmaceutical company GSK announced Tuesday that the FDA had approved its oral antibiotic Blujepa for treating uncomplicated urinary tract infections in female adults and pediatric ...